Marker Sequential Test (MaST) design

@article{Freidlin2014MarkerST,
  title={Marker Sequential Test (MaST) design},
  author={Boris Freidlin and Edward L. Korn and Robert I. Gray},
  journal={Clinical Trials},
  year={2014},
  volume={11},
  pages={19 - 27}
}
Background New targeted anticancer therapies often benefit only a subset of patients with a given cancer. Definitive evaluation of these agents may require phase III randomized clinical trial designs that integrate evaluation of the new treatment and the predictive ability of the biomarker that putatively determines the sensitive subset. Purpose We propose a new integrated biomarker design, the Marker Sequential Test (MaST) design, that allows sequential testing of the treatment effect in the… CONTINUE READING

Figures, Tables, and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.
SHOWING 1-10 OF 11 CITATIONS

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review

  • Journal of personalized medicine
  • 2017
VIEW 12 EXCERPTS
CITES METHODS, RESULTS & BACKGROUND
HIGHLY INFLUENCED

Comparison of statistical analysis plans in randomize-all phase III trials with a predictive biomarker.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2014

References

Publications referenced by this paper.
SHOWING 1-10 OF 15 REFERENCES

Phase III clinical trials that integrate treatment and biomarker evaluation.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2013
VIEW 3 EXCERPTS

Clinical trials for predictive medicine.

  • Statistics in medicine
  • 2012
VIEW 1 EXCERPT

Randomized phase II trial designs with biomarkers.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
VIEW 1 EXCERPT